IL6 and Stroke: Clinically, elevated serum levels of interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) at hospital admission correlate with significantly higher PSD risk in stroke patients (Li et al., 2022; Chen et al., 2024).